At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
LY2452473 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LY2452473 Formulation Exploratory Bioavailability Study
In Brief
A Phase 1 clinical trial evaluating LY2452473, Tadalafil, and 1 other intervention for Erectile Dysfunction. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study compares LY2452473 taken orally as a 5 milligram (mg) capsule at the same time as a 5 mg tadalafil tablet with three different combination tablets (LY900010) of 5 mg LY2452473 and 5 mg tadalafil taken orally. The study will evaluate the amount of LY2452473 and tadalafil circulating in the blood for each treatment. Side effects will be documented. This study is approximately 34 days not including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedJul 2011
Primary CompletionSep 2011
TodayJul 2026
First PostedJul 25, 2011
Enrollment StartJul 1, 2011
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.9 years ago
Interventions
LY2452473drug
Administered orally
Tadalafildrug
Administered orally
LY900010drug
Administered orally